| 前收市價 | 130.72 |
| 開市 | 130.13 |
| 買盤 | 131.25 x 900 |
| 賣出價 | 131.27 x 800 |
| 今日波幅 | 130.13 - 131.73 |
| 52 週波幅 | 99.14 - 133.10 |
| 成交量 | |
| 平均成交量 | 8,436,882 |
| 市值 | 332.258B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 145.74 |
| 每股盈利 (最近 12 個月) | 0.90 |
| 業績公佈日 | 2024年4月25日 |
| 遠期股息及收益率 | 3.08 (2.36%) |
| 除息日 | 2024年3月14日 |
| 1 年預測目標價 | 138.98 |
Motley FoolMerck (MRK) Q1 2024 Earnings Call Transcript
MRK earnings call for the period ending March 31, 2024.
BenzingaMerck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
ZacksMerck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
